Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two novel paralogous <i>C. elegans</i> proteins bind to LON-1 but do not have a major role in body size regulation.

microPublication biology·2026
Same author

Digital Volume Correlation Challenge 2.0: A Comprehensive Dataset for Digital Volume Correlation Benchmarking.

Research square·2026
Same author

Process and Structure Modeling of Architected Thermoplastic Composites Using Shape Forming Elements.

Polymers·2026
Same author

Identification of a potential internalization or endocytic compartment-targeting signal in the C-terminal tail of the tetraspanin protein TSP-12.

microPublication biology·2026
Same author

Assessing Hemodynamic Impact of Tissue-Engineered Vascular Graft Displacement: Combining Postoperative in vivo Results and Computational Modeling to Improve Surgical Planning.

ArXiv·2026
Same author

Tetraspanin TSP-12 and SUP-17/ADAM10 exhibit cell type-specific codependence for trafficking through the Golgi.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Jun 25, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Cefepime therapy and all-cause mortality.

Thao D Nguyen1, Byron Williams, Elizabeth Trang

  • 1Department of Pharmacy Services and Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California. nguyentd@ah.org

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|February 21, 2009
PubMed
Summary
This summary is machine-generated.

A 2007 meta-analysis suggested increased mortality with cefepime, prompting FDA review. This review questions the meta-analysis methodology, recommending further clinical data evaluation before altering antibiotic guidelines.

Related Experiment Videos

Last Updated: Jun 25, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Practice Guidelines

Background:

  • A 2007 meta-analysis by Yahav et al. in The Lancet Infectious Disease reported increased all-cause mortality associated with cefepime therapy.
  • The U.S. Food and Drug Administration (FDA) issued an early communication to review safety data concerning cefepime and patient mortality risk.
  • These findings and communications have initiated institutional debates regarding adjustments to antibiotic prescribing practices.

Purpose of the Study:

  • To critically review the methodology of the 2007 meta-analysis concerning cefepime and all-cause mortality.
  • To address the ongoing debate and provide recommendations for cefepime use pending further regulatory evaluation.
  • To question the validity of the meta-analysis' conclusions and advocate for a thorough clinical data review.

Main Methods:

  • Methodological review of the 2007 meta-analysis, focusing on data collection and analytical approaches.
  • Analysis of the implications of the meta-analysis findings and the FDA's early communication on clinical practice.
  • Formulation of recommendations for the appropriate use of cefepime therapy.

Main Results:

  • The review identified methodological concerns within the 2007 meta-analysis, raising questions about its conclusions on cefepime-associated mortality.
  • The study suggests that the existing evidence may be insufficient to warrant significant changes in clinical practice guidelines.
  • Debates surrounding cefepime use highlight the need for careful interpretation of meta-analytic data.

Conclusions:

  • Further comprehensive review of clinical data is essential before considering limitations or elimination of cefepime from practice guidelines.
  • Recommendations are provided for the judicious use of cefepime while awaiting further FDA guidance and analysis.
  • The study emphasizes the importance of rigorous methodological assessment in meta-analyses impacting therapeutic recommendations.